Dr. Marc Hedrick, the President and CEO of Plus Therapeutics joins Remy Blaire on this episode of Market Movers to talk about the groundbreaking work being done at CNSide Diagnostics. Discover how their innovative CNSide® Cerebrospinal Fluid (CSF) Assay Platform is revolutionizing the diagnosis and management of leptomeningeal metastases (LM), a condition that has historically seen poor survival rates.
Dr. Hedrick explains the critical need for improved diagnostics in brain and central nervous system cancers, highlighting the stark contrast in survival rates compared to other cancers over the past 40 years. Learn about the unique four-in-one test that CNSide offers, which not only confirms diagnoses but also monitors treatment effectiveness and suggests personalized treatment pathways.
The conversation also delves into the regulatory landscape, the importance of data analytics in improving patient outcomes, and the exciting future of CNSide Diagnostics as it aims to bend the curve on survival rates for patients with brain cancers.